{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:30:13Z","timestamp":1793568613731,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","aaojournal.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ophtha.2018.02.020","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T19:24:04Z","timestamp":1522178644000},"page":"1444-1451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Beh\u00e7et's Disease"],"prefix":"10.1016","volume":"125","author":[{"given":"Jos\u00e9 Luis","family":"Mart\u00edn-Varillas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Calvo-R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"S\u00e1nchez-Burs\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0270-0978","authenticated-orcid":false,"given":"Marina","family":"Mesquida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Ad\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa Hern\u00e1ndez","family":"Garfella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia Valls","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Mart\u00ednez-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00ed","family":"Sellas-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Cordero-Coma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"D\u00edaz-Llopis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Salom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Ortego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Garc\u00eda-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Luis","family":"Callejas-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Herreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Garc\u00eda-Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ma\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u00edaz-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Pato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Aurrecoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Caracuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gamero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Minguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Carrasco-Cubero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6664-6275","authenticated-orcid":false,"given":"Oscar","family":"Ruiz-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam Gand\u00eda","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Rubio-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Javier","family":"Toyos-S\u00e1enz de Miera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"L\u00f3pez Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M.","family":"Nolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-8214","authenticated-orcid":false,"given":"Marcelino","family":"Revenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gonz\u00e1lez-Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Loricera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Atienza-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosal\u00eda","family":"Demetrio-Pablo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2018.02.020_bib1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09273948.2012.723112","article-title":"Epidemiology of Beh\u00e7et disease","volume":"20","author":"Khairallah","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2018.02.020_bib2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et's disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2018.02.020_bib3","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","article-title":"Ocular features of Beh\u00e7et's disease: an international collaborative study","volume":"91","author":"Kitaichi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","article-title":"Beh\u00e7et disease: visual prognosis and factors influencing the development of visual loss","volume":"152","author":"Taylor","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: an analysis of 880 patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ophtha.2007.04.056","article-title":"Clinical features of Chinese patients with Beh\u00e7et's disease","volume":"115","author":"Yang","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.02.020_bib7","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active non-infectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2018.02.020_bib8","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitis flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2018.02.020_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10792-010-9372-1","article-title":"Effects of infliximab in the treatment of refractory posterior uveitis of Beh\u00e7et's disease after withdrawal of infusions","volume":"30","author":"Ad\u00e1n","year":"2010","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/rheumatology\/kev356","article-title":"Biologic efficacy optimization - a step towards personalized medicine","volume":"55","author":"Kiely","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2018.02.020_bib11","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/1346-8138.13001","article-title":"Adalimumab treatment optimization for psoriasis: results of a long-term phase 2\/3 Japanese study","volume":"42","author":"Asahina","year":"2015","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/11533700-000000000-00000","article-title":"Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach","volume":"70","author":"Etchevers","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ophtha.2018.02.020_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00347-016-0262-4","article-title":"Uveitis associated with juvenile idiopathic arthritis: optimization of immunomodulatory therapy","volume":"113","author":"Heiligenhaus","year":"2016","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.ophtha.2018.02.020_bib14","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","article-title":"Anti-TNF-alfa therapy in patients with refractory uveitis due to Beh\u00e7et's disease: a 1-year-follow-up study of 124 patients","volume":"53","author":"Calvo-R\u00edo","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2018.02.020_bib15","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2018.02.020_bib16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.semarthrit.2015.05.010","article-title":"Anti-TNF-\u00e1 therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients","volume":"45","author":"Riancho-Zarrabeitia","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2018.02.020_bib18","first-page":"864","article-title":"Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"4 Suppl 84","key":"10.1016\/j.ophtha.2018.02.020_bib19","first-page":"S54","article-title":"Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.ophtha.2018.02.020_bib20","first-page":"34","article-title":"The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Beh\u00e7et's disease: results of a multicentre open-label study","volume":"34 Suppl 102","author":"Santos-G\u00f3mez","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","article-title":"Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients","volume":"46","author":"Calvo-R\u00edo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2018.02.020_bib22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients","volume":"69","author":"Calvo-R\u00edo","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib23","first-page":"1","article-title":"Efficacy of anti-IL6-receptor tocilizumab in refractory cystoid macular edema of birdshot retinochoroidopathy report of two cases and literature review","volume":"11","author":"Calvo-R\u00edo","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2018.02.020_bib24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.02.020_bib25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/bjo.70.8.589","article-title":"Treatment and visual prognosis in Beh\u00e7et's disease","volume":"70","author":"Benezra","year":"1986","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","article-title":"Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease","volume":"130","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib27","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","article-title":"Adalimumab for the treatment of Beh\u00e7et's disease: experience in 19 patients","volume":"51","author":"Perra","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.ophtha.2018.02.020_bib28","first-page":"1","article-title":"Efficacy of anti-TNF-\u03b1 therapy for the treatment of non-infectious uveitis: a retrospective study of 21 patients","volume":"24","author":"Mercier","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2018.02.020_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.reuma.2010.10.003","article-title":"Efficacy of adalimumab in Beh\u00e7et's disease. Description of 6 cases","volume":"7","author":"Calvo Catal\u00e1","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.ophtha.2018.02.020_bib30","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Beh\u00e7et's disease","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2018.02.020_bib31","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3109\/09273948.2013.779727","article-title":"Long-term clinical outcomes in patients with refractory uveitis associated with Beh\u00e7et disease treated with infliximab","volume":"21","author":"Al Rashidi","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2018.02.020_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2298\/VSP1202168Z","article-title":"Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis","volume":"69","author":"Zlatanovic","year":"2012","journal-title":"Vojnosanit Pregl"},{"key":"10.1016\/j.ophtha.2018.02.020_bib33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3109\/09273948.2012.670360","article-title":"Long-term efficacy and safety of infliximab in the treatment of Beh\u00e7et's disease","volume":"20","author":"Capella","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2018.02.020_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1756-185X.12202","article-title":"Dose optimization of infliximab in patients with rheumatoid arthritis","volume":"17","author":"Alten","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ophtha.2018.02.020_bib35","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/rheumatology\/keu461","article-title":"Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis","volume":"54","author":"Gonz\u00e1lez-\u00c1lvaro","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2018.02.020_bib36","doi-asserted-by":"crossref","first-page":"PI17","DOI":"10.12659\/MSM.883250","article-title":"Do patients with active RA have differences in disease activity and perceptions if anti-TNF na\u00efve versus anti-TNF experienced? Baseline results of the optimization of adalimumab trial","volume":"18","author":"Pope","year":"2012","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ophtha.2018.02.020_bib37","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.3899\/jrheum.091447","article-title":"Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial","volume":"37","author":"Pease","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib38","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1517\/14712598.2015.1069273","article-title":"Could therapeutic drug monitoring of anti-TNF-\u03b1 be useful to consider a de-escalation of treatment?","volume":"15","author":"Flamant","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ophtha.2018.02.020_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11938-016-0079-x","article-title":"Approach to optimize anti-TNF-\u03b1 therapy in patients with IBD","volume":"14","author":"Komaki","year":"2016","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/17512433.2016.1133288","article-title":"Optimization of anti-TNF therapy in patients with inflammatory bowel disease","volume":"9","author":"Strik","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ophtha.2018.02.020_bib41","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1097\/MIB.0000000000000772","article-title":"Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug\u00a0antibodies","volume":"22","author":"Steenholdt","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ophtha.2018.02.020_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et's disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"}],"updated-by":[{"DOI":"10.1016\/j.ophtha.2018.10.039","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000}}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017333900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017333900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T11:07:10Z","timestamp":1534936030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642017333900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0161642017333900"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.02.020","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ophtha.2018.10.039","asserted-by":"object"}]},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Beh\u00e7et's Disease","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}